Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
REDWOOD CITY, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on January 15, 2016, the compensation committee of the company’s board of directors granted 12 new employees options to purchase an aggregate of 39,000 shares of the company’s common stock with a per share exercise price of $19.44, the closing trading price on the grant date, and 19,500 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, VeltassaTM (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
